Trial Profile
Study of 18 F-THK5351 PET to predict the prognosis for mild cognitive impairment (MCI) due to Alzheimer's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 May 2018
Price :
$35
*
At a glance
- Drugs Fluorine 18 THK 5351 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Diagnostic use
- 28 May 2018 New trial record
- 05 May 2018 Results presented at the 2018 Annual Scientific Meeting of the American Geriatrics Society